Compare PDX & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDX | TBPH |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.1M | 824.9M |
| IPO Year | N/A | 2013 |
| Metric | PDX | TBPH |
|---|---|---|
| Price | $21.75 | $16.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.40 |
| AVG Volume (30 Days) | 92.4K | ★ 282.6K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | N/A | $8.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.47 | $9.10 |
| 52 Week High | $25.25 | $21.03 |
| Indicator | PDX | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 46.74 |
| Support Level | $21.50 | $16.14 |
| Resistance Level | $22.14 | $17.21 |
| Average True Range (ATR) | 0.32 | 0.38 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 76.92 | 29.31 |
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.